Comments on the Evaluation of Suicidality Risk of Newer Antiseizure Medications

JAMA Neurol. 2022 Mar 1;79(3):309-310. doi: 10.1001/jamaneurol.2021.5138.

Authors

Jummai Apata¹, Andrew Mosholder¹, Mark Levenson²

Affiliations

¹ Division of Epidemiology I, US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland.
² Division of Biometrics 7, US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland.

PMID: 35099515
DOI: 10.1001/jamaneurol.2021.5138

No abstract available

Publication types

Comment

MeSH terms

Anticonvulsants / adverse effects
Disease Susceptibility
Epilepsy* / drug therapy
Humans
Suicide Prevention*

Substances

Anticonvulsants